| News Updates |
| |
| 27-Jan-2010 |
Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone |
| |
Bangalore, India, January 27, 2010 -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals (Nasdaq: ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone. |
| 11-Jan-2010 |
DiscoveRx Corp. & Jubilant Biosys Limited
announce Co-Marketing Agreement for Screening Services |
| |
Jubilant Biosys Limited, based in Bangalore, an integrated Drug Discovery and Development solution provider, a subsidiary of Jubilant Organosys Ltd, headquartered in Noida, announced today that it has entered into a co-marketing agreement to provide screening solutions, with DiscoveRx Corporation (Fermont, USA), a premier provider of innovative cell based assay solutions for GPCR, Kinases, NHR and Proteases. |
|
15-Dec-2009 |
Hari S Bhartia, Co-chairman and Managing Director of
Jubilant Organosys awarded person of the year at 7th Biospectrum awards 2009 |
| |
|
|
01-Dec-2009 |
Jubilant and Lilly
Extend Drug Discovery Collaboration on Successful Delivery
of
Pre-clinical Candidates |
| |
Jubilant
Organosys Ltd.,through its subsidiary Jubilant Biosys Ltd
based in Bangalore announced today that its 4 year old
research collaboration with Eli Lilly & Company, has
successfully delivered multiple discovery milestones and
preclinical candidates, resulting in a five-year extension
and an expanded portfolio collaboration. |
| |
|
|
23-Nov-2009 |
Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture |
| |
BIRMINGHAM, Ala. USA/ Noida (UP) India.Nov. 23, 2009.Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S-India
arbitraged and leveraged partnership that will accelerate
the development of affordable therapies for patients
worldwide. A Memorandum of Understanding was signed today in
Washington, DC. |
| |
|
| 10-Nov-2009 |
Duke University & Jubilant Organosys Announce Intent to Enter Global Research and Drug Development Partnership |
| |
Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies. The proposed partnership will also advance both organizations' mutual commitment to reducing global health disparities. The Parties shall complete definitive agreements by the first quarter of 2010. |
| |
|
| 11-Jun-2009 |
Jubilant to work with Endo Pharmaceuticals on Drug development |
| |
Jubilant
Organosys Ltd., headquartered in Noida, announced today that
its Bangalore-based subsidiary, Jubilant Biosys Ltd., has
entered into a discovery and development collaboration with
Endo Pharmaceuticals, a US-based pharmaceutical company. As
part of the agreement, Jubilant and Endo would collaborate
initially to develop a portfolio of targets in the area of
Oncology, with a focus on delivering preclinical candidates
that could be selected for joint clinical development. |
| |
|
|
05-May-2009 |
Jubilant
Enters Research Collaboration with AstraZeneca |
| |
Jubilant
Organosys Ltd, headquartered in India, announced today that
its Bangalore, India, based subsidiary,Jubilant Biosys Ltd,
has signed a research collaboration agreement with,
AstraZeneca, and focused on delivering novel drug candidates
into the international pharmaceutical company's pre-clinical
pipeline. Under the shared risk-reward collaboration, which
will initially focus on the neuroscience area, Jubilant aims
to deliver a steady stream of discovery programs to
AstraZeneca. |
| |
|
| 09-Apr-2009 |
Jubilant
and Orion "Hybrid and Integrated " Discovery
Collaboration |
| |
Jubilant
Organosys Ltd, headquartered at NOIDA, announced today that
is subsidiaries Jubilant Biosys limited (Bangalore based)
and jubilant Chemsys Ltd(Noida based ) have entered into
three way drug discovery partnership with Orion , a leading
pharmaceutical company of Finland. Under this "Hybrid
& Integrated" arrangement, Orion will have the
option of utilizing resources flexibility from Jubilant
Biosys Ltd and Jubilant Chemsys Ltd Based on the requirement
of its drug discovery projects. |
| |
|